Literature DB >> 21764403

Important role of population pharmacokinetic/pharmacodynamic modeling in pediatric therapeutics.

Alexander A Vinks.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21764403     DOI： 10.1016/j.jpeds.2011.05.041

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  6 in total

1.  Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.

Authors:  Carl Amilon; Mohammad Niazi; Anders Berggren; Magnus Åstrand; Bengt Hamrén
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

Review 2.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

3.  Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-02-05       Impact factor: 4.335

4.  Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.

Authors:  Yewei Chen; Dan Wu; Min Dong; Yiqing Zhu; Jinmiao Lu; Xiaoxia Li; Chao Chen; Zhiping Li
Journal:  Eur J Clin Pharmacol       Date:  2018-03-30       Impact factor: 2.953

5.  Federal legislation and the advancement of neonatal drug studies.

Authors:  Jason R Wiles; Alexander A Vinks; Henry Akinbi
Journal:  J Pediatr       Date:  2012-10-27       Impact factor: 4.406

6.  Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.

Authors:  Brian A Moser; Elizabeth S LaBell; Emmanuel Chigutsa; Joseph A Jakubowski; David S Small
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.